

ALLERGAN INC
Form 11-K
June 13, 2013
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 11-K

(Mark One):

ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2012

OR

TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 1-10269

ALLERGAN, INC.
SAVINGS AND INVESTMENT PLAN

(Full title of the plan)

ALLERGAN, INC.

2525 Dupont Drive

Irvine, California 92612

(Name of issuer of the securities held

pursuant to the plan and the address of its

Edgar Filing: ALLERGAN INC - Form 11-K

principal executive office)

Table of Contents

REQUIRED INFORMATION

4. ERISA Financial Statements and Schedule and Exhibits:

(a) Financial Statements and Schedule:

Report of Independent Registered Public Accounting Firm of Lesley, Thomas, Schwarz & Postma, Inc., dated June 13, 2013, on the Statements of Net Assets Available for Benefits as of December 31, 2012 and 2011 and the related Statements of Changes in Net Assets Available for Benefits for the Years Then Ended Allergan, Inc. Savings and Investment Plan.

Statements of Net Assets Available for Benefits as of December 31, 2012 and 2011 Allergan, Inc. Savings and Investment Plan.

Statements of Changes in Net Assets Available for Benefits for the Years Ended December 31, 2012 and 2011 Allergan, Inc. Savings and Investment Plan.

Notes to Financial Statements Allergan, Inc. Savings and Investment Plan.

Schedule H, Line 4i Schedule of Assets (Held at End of Year) December 31, 2012 Allergan, Inc. Savings and Investment Plan.

(b) Exhibits

Exhibit 23 Consent of Lesley, Thomas, Schwarz & Postma, Inc.

SIGNATURE

The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLERGAN, INC. SAVINGS

AND INVESTMENT PLAN

Date: June 13, 2013

By: /s/ Jeffrey L. Edwards
Jeffrey L. Edwards
Allergan, Inc.
Executive Committee

Table of Contents

ALLERGAN, INC.

SAVINGS AND INVESTMENT PLAN

INDEX TO FINANCIAL STATEMENTS

AND SUPPLEMENTAL SCHEDULE

	Page
<u>Report of Independent Registered Public Accounting Firm</u>	1
<u>Statements of Net Assets Available for Benefits – December 31, 2012 and 2011</u>	2
<u>Statements of Changes in Net Assets Available for Benefits for the Years Ended December 31, 2012 and 2011</u>	3
<u>Notes to Financial Statements</u>	4
<u>SUPPLEMENTAL SCHEDULE</u>	
<u>Schedule H, Line 4i – Schedule of Assets (Held At End of Year) – December 31, 2012</u>	19
EXHIBIT 23	
<i>All other schedules are omitted because they are not required or applicable pursuant to ERISA and Department of Labor regulations.</i>	

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Executive Committee of Allergan, Inc.

Irvine, California

We have audited the accompanying statements of net assets available for benefits of the Allergan, Inc. Savings and Investment Plan as of December 31, 2012 and 2011, and the related statements of changes in net assets available for benefits for the years then ended. These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Plan's internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for benefits of the Allergan, Inc. Savings and Investment Plan as of December 31, 2012 and 2011, and the changes in net assets available for benefits for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Our audits were performed for the purpose of forming an opinion on the basic financial statements taken as a whole. The accompanying supplemental schedule of Schedule H, Line 4i Schedule of Assets (Held at End of Year) as of December 31, 2012 is presented for the purpose of additional analysis and is not a required part of the basic financial statements but is supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. This supplemental schedule is the responsibility of the Plan's management. The supplemental schedule has been subjected to the auditing procedures applied in the audits of the basic financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

/s/ Lesley, Thomas, Schwarz & Postma, Inc.

Lesley, Thomas, Schwarz & Postma, Inc.

Newport Beach, California

June 13, 2013

Table of Contents**ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN****STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS****DECEMBER 31, 2012 AND 2011**

	2012	2011
ASSETS		
Investments in master trust at fair value (Note 3)	\$ 852,328,623	\$ 712,099,334
Receivables		
Employer contributions	24,051,460	21,610,121
Notes receivable from participants	10,929,084	10,264,029
Total receivables	34,980,544	31,874,150
Net assets available for benefits before adjustment to contract value	887,309,167	743,973,484
Adjustment from fair value to contract value for fully benefit-responsive investment contract (Note 2)	(1,605,762)	(196,209)
NET ASSETS AVAILABLE FOR BENEFITS	\$ 885,703,405	\$ 743,777,275

See the accompanying notes to these financial statements

Table of Contents**ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN****STATEMENTS OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS****FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011**

	2012	2011
ADDITIONS TO NET ASSETS ATTRIBUTED TO:		
Net investment income from the Master Trust (Note 3)	\$ 89,523,961	\$ 24,741,094
Interest from notes receivable from participants	462,969	459,898
Contributions		
Employer match	19,992,265	18,473,148
Employer retirement	22,846,650	20,573,877
Participant before tax	45,160,101	40,847,171
Participant after tax	2,132,538	1,227,372
Rollovers	7,120,268	5,609,860
	97,251,822	86,731,428
Total additions to net assets	187,238,752	111,932,420
DEDUCTIONS FROM NET ASSETS ATTRIBUTED TO:		
Benefits paid to participants	45,231,847	39,415,957
Corrective distributions	13,086	3,763
Deemed distributions	36,735	1,453
Administrative expenses	30,954	64,879
Total deductions from net assets	45,312,622	39,486,052
NET INCREASE	141,926,130	72,446,368
NET ASSETS AVAILABLE FOR BENEFITS, beginning of year	743,777,275	671,330,907
NET ASSETS AVAILABLE FOR BENEFITS, end of year	\$ 885,703,405	\$ 743,777,275

See the accompanying notes to these financial statements

Table of Contents

ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN

NOTES TO FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011

NOTE 1 DESCRIPTION OF THE PLAN

The following description of the Allergan, Inc. Savings and Investment Plan (Restated 2011) (the Plan) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan's provisions.

General The Plan, established on July 26, 1989, is a defined contribution plan sponsored by Allergan, Inc. (the Company). The Plan covers eligible employees of the Company as defined below. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (ERISA) and is qualified under the Internal Revenue Code (the Code). The administrator for the Plan is the Allergan, Inc. Global Investments and Benefits Subcommittee. The trustee for the Plan is JPMorgan Chase Bank.

Employee Contributions The Plan provides for immediate eligibility to participate in the Plan. The Company's eligible United States employees may contribute a portion of their defined compensation, on a before tax, Roth 401(k), or after tax basis, or a combination thereof, subject to the limitations as defined by the Code.

The Company's eligible Puerto Rico employees may contribute a portion of their defined compensation, either before tax, after tax, or a combination thereof, subject to the limitations as defined by the Puerto Rico Internal Revenue Code.

Participants direct the investment of their contributions into various investment options offered by the Plan through the Master Trust. The plan administrator, or its delegate, regularly consults with an investment advisor to evaluate investment performance and, based thereon, will add or remove investment options. Prior to August 15, 2011, participant contributions could be invested in the Allergan, Inc. Common Stock Fund, Dodge & Cox Balanced Fund, Dodge & Cox Stock Fund, Columbia Marsico Focused Equities Fund, Times Square Small Cap Growth Fund, TIAA-CREF Small Cap Blend Index Fund, Pimco Total Return-Inst Fund, American Funds EuroPacific Growth R6 Fund, American Funds New Perspective R6 Fund, JPMorgan U.S. Equity Fund, Nuveen Winslow Large Cap Growth Fund, Wells Fargo Advantage Special Small Cap Value Fund, JPMorgan Stable Value Fund, BlackRock Equity Index Fund, or any combination of the 14 funds at the participant's discretion.

Effective August 15, 2011, JPMorgan Stable Value Fund was removed from the investment options and JPMCB Stable Asset Income Fund Select was added to the investment options.

Effective June 29, 2012, JPMCB Stable Asset Income Fund Select was removed from the investment options and JPMCB Stable Asset Income Fund G was added to the investment options.

Effective December 28, 2012, Columbia Marsico Focused Equities Fund and Dodge & Cox Balanced Fund were removed from the investment options and LifePath Index Retirement Fund, LifePath Index 2015 Fund, LifePath Index 2020 Fund, LifePath Index 2025 Fund, LifePath Index 2030 Fund, LifePath Index 2035 Fund, LifePath Index 2040 Fund, LifePath Index 2045 Fund, LifePath Index 2050 Fund, and LifePath Index 2055 Fund were added to the investment options.

Certain limitations imposed by the Code may have the effect of reducing the level of contributions initially selected by participants who fall within the classification of highly compensated employees as defined in the Code.

Employer Matching Contributions The Plan authorizes the Company's Board of Directors, or its delegate, to change the Company's matching contribution levels from time to time in an amount not to exceed 4% of each employee's defined compensation. For the years ended December 31, 2012 and 2011, the Employer made matching contributions equal to 100% of each employee's contribution up to 4% of defined compensation.

Table of Contents

ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011

NOTE 1 DESCRIPTION OF THE PLAN (CONTINUED)

Employer Retirement Contributions Effective January 1, 2003, the Company makes an annual retirement contribution equal to 5% of each participant's defined compensation if they are eligible for the Retirement Contribution feature of the Plan, have completed at least six months of service, and are employed on the last business day of the year (or terminated employment during the year due to death, disability or retirement, defined as age 55+). In addition, the Company has discretion to make supplemental retirement contributions in the future years as necessary to satisfy applicable non-discrimination requirements set forth under the Code.

Investment Options Participants have the right to elect investment options upon enrollment or re-enrollment into the Plan. Additionally, participants may elect to change their investment options and transfer their account balances among the different investment funds at any time, subject to the Company's insider trading policy.

Participant Accounts Each participant's account is credited for the participant's contributions, employer match and employer retirement contributions and allocations of fund earnings and charged with an allocation of administrative expenses and fund losses. The earnings and losses of each of the funds are allocated daily to the individual accounts of participants based on their relative interest in the fair value of the assets held in each fund, except for dividends and unrealized appreciation (depreciation) on the common stock of Allergan, Inc., which is allocated based upon the number of shares held in the individual accounts of participants.

Notes Receivable from Participants Participants may borrow from their fund accounts a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 or 50% of their vested account balance excluding retirement contributions. Loan terms range from one to five years or, for the purchase of a primary residence, up to 15 years. The loans are secured by the balance in the participant's account and bear interest at prime plus one percent as determined on the date of the loan application. The interest rate is fixed for the term of the loan. Principal and interest is paid through payroll deductions each pay period. Defaults on participant loans are considered to be deemed distributions. The Plan classified participant loans as notes receivable from participants in the Statements of Net Assets Available for Benefits and measured them at their unpaid principal balance plus any accrued interest.

Vesting and Forfeitures Participant contributions are fully vested at all times. Participants forfeit their share of non-vested employer contributions if they terminate their employment before becoming 100% vested. Employer matching contributions vest based on a cliff vesting of three years of service. After three years of service, all employer matching contributions are fully vested. Employer retirement contributions vest on a graduated basis, 20% per year until fully vested at the end of the fifth year of service. Forfeitures are used by the Company to offset future employer contribution requirements and to reinstate rehired employee accounts. During the Plan years ended December 31, 2012 and 2011, \$2,986,559 and \$1,934,892, respectively, of forfeitures were used to offset contributions. At December 31, 2012 and 2011, unutilized forfeitures totaled \$146,103 and \$17,709, respectively.

Table of Contents

ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011

NOTE 1 DESCRIPTION OF THE PLAN (CONTINUED)

Payment of Benefits Participants may withdraw their employee after-tax and rollover contributions at any time. After withdrawing all after-tax and rollover contributions, vested employer matching contributions can also be withdrawn at any time by a participant who has at least three years of credited service provided that the matching contributions were credited at least two years prior to withdrawal. Withdrawals of employee after-tax contributions during employment may cause the participant to become ineligible to receive certain employer matching contributions and be suspended from contributing to the Plan for a period of six months following the withdrawal.

After the permitted withdrawal of employee after-tax contributions, rollover contributions and vested employer matching contributions in accordance with the prior paragraph, and upon receipt of any loans available under the Plan, an employee may withdraw his or her before-tax contributions and any remaining after-tax contributions and vested employer matching contributions in the event of financial hardship. Hardship withdrawals cause the employee to become ineligible to contribute to the Plan for a period of six months following the withdrawal for U.S. employees and 12 months for Puerto Rico employees. Hardship withdrawals of employer retirement contributions are not permitted.

Participants become entitled to payment of the total value of their accounts at the time of termination (if fully vested), attainment of age 59-1/2 (if fully vested), permanent and total disability, or death. Under certain circumstances set forth in the Plan, the participant may elect to receive the distribution in a lump sum or may elect partial distributions. If the participant's vested account value is \$1,000 or more, withdrawals may be postponed until as late as attaining age 70-1/2. After death, payment is made in the form of a lump sum to the designated beneficiary.

Special rules apply to Roth 401(k) contributions. While they are subject to the same distribution restrictions applicable to before-tax contributions, the participant must meet two conditions to have a qualified distribution that allows the Roth 401(k) earnings to be tax free. First, the Roth 401(k) source must have been in existence in the account for at least five years. Second, the distributions must be after age 59-1/2, death or disability.

NOTE 2 SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting The accompanying financial statements have been prepared on the accrual basis of accounting. Except for unutilized forfeitures (see Note 1), the net assets of the Plan are allocated entirely to individual participants' accounts.

The Statements of Net Assets Available for Benefits present the fair value of the investment contracts as well as the adjustment of the fully benefit-responsive investment contracts from fair value to contract value. The Statements of Changes in Net Assets Available for Benefits are prepared on a contract value basis.

Accounting Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the plan administrator to make estimates and assumptions that affect the reported amounts of assets, liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Investment Valuation and Income Recognition On June 20, 2007, the Plan, along with the Allergan, Inc. Employee Stock Ownership Plan, entered into the Allergan, Inc. Master Trust (the "Master Trust"). See Note 3, for further discussion of the Master Trust. The Plan's investments in the Master Trust are stated at fair value with the exception of the JPMCB Stable Asset Income Fund - G and the JPMCB Stable Asset Income Fund - Select which are stated at their fair values with the related adjustment amounts to their contract values.

The following presentation relates to the fully benefit-responsive investment contracts (JPMCB Stable Asset Income Fund - G for 2012 and JPMCB Stable Asset Income Fund - Select for 2011) held in the Master Trust for the years ended December 31, 2012 and 2011:

Edgar Filing: ALLERGAN INC - Form 11-K

(a) The accounts are credited with earnings on the underlying investments and charged for participant withdrawals and administrative expenses. The contracts are included in the financial statements at fair value with adjustments to contract value as reported to the Plan by JPMorgan Chase Bank.

Table of Contents

ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011

NOTE 2 SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

(b) The fair value of the Plan's investment contracts in the Master Trust at December 31, 2012 and 2011 was \$89,721,362 and \$79,122,829, respectively. The contract value of the investment contracts at December 31, 2012 and 2011 was \$88,115,600 and \$78,926,620, respectively.

(c) There are no reserves against the contract value for credit risk of the contract issuer or otherwise. The average yields at December 31, 2012 and 2011 were approximately 1.78% and 2.18%, respectively. The crediting interest rate is based on an agreed-upon formula with the insurer, but cannot be less than zero. This rate is reset each calendar quarter based on the data as of the last business day of the month prior to the end of the quarter. The crediting interest rates in effect at December 31, 2012 and 2011 were approximately 1.81% and 2.18%, respectively. Participant initiated transactions occur at contract value.

Purchases and sales of investments held in the Master Trust are reflected on the trade-date basis. Dividend income is recorded on the ex-dividend date.

The Plan presents, in the Statements of Changes in Net Assets Available for Benefits, the net appreciation (depreciation) in the contract value of its investments held in the Master Trust, which consist of the realized gains or losses and the unrealized appreciation (depreciation) on those investments held in the Master Trust.

Contribution Funding The participant deferrals and employer matching contributions are funded on a consistent basis following the issuance of each Company payroll. Employer retirement contributions and matching contribution true-ups are funded on an annual basis.

Non-Discrimination for Employee and Employer Contributions The Plan, as required by the Code, performs annual tests between participants who are highly compensated employees and those who are non-highly compensated employees to ensure that highly compensated employees are not disproportionately favored under the Plan. If the Plan fails the tests, it must refund some of the excess contributions made on behalf of highly compensated employees during the applicable year. Excess contributions that are refunded are accrued as a liability of the Plan in the year to which they relate. No such accrual exists at December 31, 2012 and 2011.

Non-Distributed Benefits The Plan does not accrue non-distributed benefits related to participants who have withdrawn from the Plan, but recognizes such benefits as a deduction from net assets in the period in which such benefits are paid.

Continuation of the Plan The Company anticipates and believes the Plan will continue without interruption, but reserves the right to discontinue the Plan. If the Plan is terminated by the Company, the accounts of all affected participants shall become 100% vested and non-forfeitable without regard to the years of service of such participants.

Administrative Expenses Expenses incurred in the administration and operation of the Plan are paid by the Plan, except to the extent paid by the Company. Certain administrative expenses of the Plan are paid by the Company.

Accounting Pronouncements In May 2011, the Financial Accounting Standards Board issued an accounting standards update that clarifies and amends the existing fair value measurement and disclosure requirements. This guidance became effective for the Plan's financial statements for the year ended December 31, 2012. The adoption of the provisions of this guidance did not have a material impact on the Plan's financial statements.

Subsequent Events On December 19, 2012, the Company completed the acquisition of SkinMedica, Inc. Pursuant to a Plan amendment, employees of SkinMedica, Inc. became eligible to participate in the Plan effective January 1, 2013.

Table of ContentsALLERGAN, INC. SAVINGS AND INVESTMENT PLANNOTES TO FINANCIAL STATEMENTS (CONTINUED)FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011**NOTE 2 SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

The Plan was restated in its entirety on January 1, 2013 to incorporate the provisions of all amendments made since the last restatement of the Plan in 2011.

On March 1, 2013, the Company completed the acquisition of MAP Pharmaceuticals, Inc. (MAP). Pursuant to a Plan amendment, employees of MAP became eligible to participate in the Plan effective June 1, 2013.

On April 12, 2013, the Company completed the acquisition of Exemplar Pharma, LLC (Exemplar). Pursuant to a Plan amendment, employees of Exemplar became eligible to participate in the Plan effective June 1, 2013.

The Company has evaluated subsequent events through the date which the financial statements were available to be issued.

NOTE 3 INVESTMENTS

The Master Trust was created pursuant to a trust agreement dated June 20, 2007, between the Company and JPMorgan Chase Bank, as trustee of the funds, to permit the commingling of trust assets of both the Allergan, Inc. Savings and Investment Plan and Allergan, Inc. Employee Stock Ownership Plan, for investment and administrative purposes. The assets of the Master Trust are held by JPMorgan Chase Bank.

The following tables summarize the net assets at fair value and net investment income of the Master Trust.

A) NET ASSETS OF THE MASTER TRUST

	December 31, 2012	December 31, 2011
INVESTMENTS:		
Mutual Funds	\$ 418,368,982	\$ 417,795,241
Common/Collective Trusts	296,226,295	153,825,927
Employer Securities	317,420,055	318,897,550
NET ASSETS OF THE MASTER TRUST	\$ 1,032,015,332	\$ 890,518,718

NET INVESTMENT IN MASTER TRUST BY PLAN

Allergan, Inc. Savings and Investment Plan		
Investment in Master Trust	\$ 852,328,623	\$ 712,099,334
Plan's percentage interest in net assets of the Master Trust	82.6%	80.0%
Allergan, Inc. Employee Stock Ownership Plan		
Investment in Master Trust	\$ 179,686,709	\$ 178,419,384

Edgar Filing: ALLERGAN INC - Form 11-K

Plan's percentage interest in net assets of the Master Trust

17.4%

20.0%

Table of ContentsALLERGAN, INC. SAVINGS AND INVESTMENT PLANNOTES TO FINANCIAL STATEMENTS (CONTINUED)FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011**NOTE 3 INVESTMENTS (CONTINUED)**

B) NET INVESTMENT INCOME OF THE MASTER TRUST

	Year Ended December 31, 2012	Year Ended December 31, 2011
INVESTMENT INCOME:		
Net appreciation (depreciation) in fair value of investments		
Common Stock	\$ 14,563,255	\$ 71,810,257
Mutual Funds	56,199,119	(28,875,141)
Common/Collective Trusts	14,369,384	3,740,669
U.S. Government Securities		26,935
	85,131,758	46,702,720
Change in adjustment from fair value to contract value for fully benefit-responsive investment contracts	(1,526,952)	(715,964)
Dividends	17,463,507	10,113,552
NET INVESTMENT INCOME OF THE MASTER TRUST	\$ 101,068,313	\$ 56,100,308
NET INVESTMENT INCOME FROM MASTER TRUST BY PLAN		
Allergan, Inc. Savings and Investment Plan	\$ 89,523,961	\$ 24,741,094
Allergan, Inc. Employee Stock Ownership Plan	\$ 11,544,352	\$ 31,359,214

Table of Contents**ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN****NOTES TO FINANCIAL STATEMENTS (CONTINUED)****FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011****NOTE 3 INVESTMENTS (CONTINUED)**

The following table presents the fair value of the Plan's investments held in the Master Trust. Investments that represent five percent or more of the Plan's net assets available for benefits at December 31, 2012 and 2011 are separately identified.

	December 31, 2012	
	Number of Shares, Units or Principal	
	Amounts	Fair Value
PARTICIPANT DIRECTED INVESTMENTS		
At fair value as determined by quoted market prices (held in Master Trust):		
Common Stock:		
Allergan, Inc.*	1,939,824	\$ 177,940,048
Mutual Funds:		
Dodge & Cox Stock Fund	188,734	23,006,652
Times Square Small Cap Growth Fund	1,496,591	19,455,688
TIAA-CREF Small Cap Blend Index Fund	1,824,549	25,872,108
Pimco Total Return-Inst Fund*	6,463,378	72,648,368
American Funds EuroPacific Growth R6 Fund*	1,948,447	80,237,063
American Funds New Perspective R6 Fund*	2,805,432	87,669,765
JPMorgan U.S. Equity Fund	3,300,187	37,061,104
Nuveen Winslow Large Cap Growth Fund	883,102	30,087,273
Wells Fargo Advantage Special Small Cap Value Fund	893,009	